Truveta announces collaboration with Boston Scientific to advance post-procedure patient insights and help address healthcare disparities

3202

truvetaTruveta announced a strategic collaborative agreement with Boston Scientific to improve long-term patient care and gain insights into healthcare disparities. Through this collaboration, Boston Scientific researchers will be able to access data from Truveta, which contains de-identified medical records from more than 65 million US patients.

“Truveta will enable us to gather insights on a breadth of devices and disease states, including peripheral artery disease (PAD), venous thromboembolic disease, and segments of interventional oncology,” said Michael Jaff, vascular medicine specialist and chief medical officer and vice president, Medical Affairs, Innovation and Technology, Peripheral Interventions, Boston Scientific. “The first analysis will focus on gaining a deeper understanding of the long-term patient outcomes relating to the use of our products indicated for treatment of PAD.”

According to the US Centers for Disease Control, PAD affects approximately 6.5 million people aged 40 and older in the USA. This month is PAD Awareness Month, and Truveta recently shared new insights from its de-identified data, including findings that of the more than 11,000 PAD patients who received revascularisation procedures, Black or African American patients with PAD (1.0%) were less likely to undergo revascularisation than white patients diagnosed with PAD (2.6%). Of those who are treated with an interventional procedure, Black or African American patients were also less likely to receive drug-eluting stents than their white counterparts. Additionally, insights into major adverse outcomes, like lower-limb amputation, were discovered. For example, patients treated with drug-eluting stents had lower rates (4.8%) of amputation compared to all patients who received revascularisation (8.5%).

“Device manufacturers realise it is critical to have data on the clinical outcomes for patients treated with their devices following regulatory approvals, yet those data can be messy, fragmented, and difficult to obtain and analyse,” said Terry Myerson, chief executive officer of Truveta. “Truveta solves this problem, empowering researchers with real-world data on how any drug or device is currently being used every day across the USA.”

Truveta data provide the most up-to-date picture of US health across age, race, ethnicity, geography, socioeconomic factors, and more. Data are updated daily and include the full Electronic Medical Record (EMR), including device-specific data, not just the medical bill from claims data, all de-identified and aggregated

These clinical data are linked across providers and with medical claims when care is provided outside Truveta’s network. Every patient record is enhanced with comprehensive socioeconomic data and daily mortality data for a complete picture of each patient’s health journey without risk of re-identification.

“The COVID-19 pandemic put a spotlight on the importance of data to inform and improve patient care. It also put a glaring spotlight on the inequities in accessing and receiving equitable healthcare that are prevalent among people of colour and low-income communities throughout the USA,” said Debbie Salas-Lopez, Community and Population Health at Northwell Health and Truveta Ethics and Health Equity Board of Governors member.


LEAVE A REPLY

Please enter your comment!
Please enter your name here